In treatment, drug testing should support recovery and clinical decision-making. It can help identify recent use, medication adherence, emerging risks, and the need to adjust care. It should not replace trust, self-report, or a therapeutic relationship.
Define the clinical purpose
Testing may monitor progress, guide medication decisions, support contingency management, or detect substances that increase overdose risk. The program should explain the purpose, schedule, specimen, panel, and response to results.
Scheduled and random testing
Predictable testing can help routine monitoring; clinically appropriate random testing may reduce the chance that results reflect only a planned abstinence interval. Frequency should be individualized and adjusted as risk and stability change.
Choose the right panel
The panel should include treatment medications and locally relevant substances when results will affect care. Standard screens can miss fentanyl, buprenorphine, methadone, or certain benzodiazepines. Testing everything without a clinical plan adds cost and can reveal irrelevant information.
Medication treatment is not treatment failure
Expected detection of methadone or buprenorphine prescribed for opioid use disorder should be interpreted as medication exposure, not illicit opioid use. Metabolite patterns and definitive methods can sometimes help evaluate whether medication was taken.
Responding to recurrence of use
A positive result may signal a need for more support, overdose prevention, medication adjustment, or a higher level of care. Automatic discharge can increase risk. Discuss the result nonjudgmentally, confirm unexpected screens, and revise the treatment plan.
Privacy
Substance-use-disorder treatment records may receive special protection under 42 CFR Part 2 in addition to HIPAA. Consent and disclosure rules depend on the provider and purpose. Court, employer, or probation involvement should be explained before testing.
Good-program features
- transparent written procedures;
- individualized frequency and panel;
- definitive testing for consequential discrepancies;
- qualified interpretation;
- nonstigmatizing language;
- overdose prevention and naloxone access; and
- a clinical response rather than reflex punishment.
Sources
Medical review: October 29, 2026.